bluebird bio, Inc. (NASDAQ:BLUE) Files An 8-K Other Events

bluebird bio, Inc. (NASDAQ:BLUE) Files An 8-K Other Events
Item 8.01Other Events.

Story continues below

On December 1, 2018, bluebird bio, Inc. (“bluebird”) issued a press release announcing data presented at the 60th Annual Meeting of the American Society of Hematology (“ASH”) from the completed Phase 1/2 Northstar (HGB-204) study of investigational LentiGlobin product candidate in patients with transfusion-dependent β-thalassemia and from the ongoing Phase 1/2 HGB-206 study (Groups A and B) of LentiGlobin product candidate in patients with sickle cell disease.

On December 2, 2018, bluebird issued a press release announcing data presented at ASH from the ongoing Phase 1 clinical study of bb21217 (CRB-402) of its investigational next-generation anti-BCMA CAR T cell therapy being investigated in relapsed-refractory multiple myeloma.

The full text of bluebird’s press releases regarding these announcements are filed as Exhibits 99.1 and 99.2 to this Current Report on Form 8-K and are incorporated herein by reference.

Item 9.01Financial Statements and Exhibits.

(d) Exhibits


bluebird bio, Inc. Exhibit
EX-99.1 2 blue-ex991_6.htm EX-99.1 blue-ex991_6.htm     Exhibit 99.1     bluebird bio Presents Updated Data from Clinical Studies of LentiGlobin Gene Therapy in Transfusion-Dependent β-Thalassemia and Sickle Cell Disease at 60th Annual Meeting of the American Society of Hematology   All patients with transfusion-dependent β-thalassemia and a non-β0/β0 genotype who achieved transfusion independence continue to maintain it for up to 3.5 years in Phase 1/2 Northstar (HGB-204) study   HbAT87Q levels were stable and vaso-occlusive events were reduced in most Group A and B patients with sickle cell disease in Phase 1/2 HGB-206 study following treatment with LentiGlobin   CAMBRIDGE,…
To view the full exhibit click here

About bluebird bio, Inc. (NASDAQ:BLUE)

bluebird bio, Inc. is a biotechnology company. The Company is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy. Its gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder. Its oncology programs are built using lentiviral gene delivery and T cell engineering, with a focus on developing T cell-based immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies. Its oncology program, bb2121, is a CAR T cell product candidate targeting B-cell maturation antigen, or BCMA, in multiple myeloma. It also offers discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies for use across its pipeline.

An ad to help with our costs